(BMC Med Genomics[TA])
2,902 results
  • Development and pilot testing of a prostate cancer polygenic risk report. [Randomized Controlled Trial]
    BMC Med Genomics. 2026 Jul 30; 19(1).Griffin JN, Danowski ME, … Vassy JLBM
  • CONCLUSIONS: In this qualitative pilot study, patient-facing materials for communicating prostate cancer PRS were generally well received, with specific design features such as simple visualizations and clear formatting enhancing understanding. Findings highlight the importance of intuitive risk displays and actionable guidance in PRS reporting. These results provide practical insights to inform the design of genomic risk reports as PRS-based prostate cancer screening approaches move toward clinical implementation.
  • A real-time PCR-based noninvasive prenatal RHD screening assay optimized for population-specific RHD allelic spectra in China. [Journal Article]
    BMC Med Genomics. 2026 Aug 08; 19(1).Wei X, Jiang L, Zhu QBM
  • CONCLUSIONS: This study presents a methodological framework for noninvasive prenatal RHD genotyping, specifically optimized for Chinese and other East Asian populations. Assay performance relies on distinct amplification patterns of population-specific RHD alleles across exons 5, 9, and 10. In addition, inclusion of exon 5 allows detection of RHD variants frequently observed in African populations, suggesting potential applicability across genetically diverse populations, pending further population-specific validation.
  • Benchmarking sequence-based and AlphaFold-based methods for pMHC-II binding core prediction: distinct strengths and consensus approaches. [Journal Article]
    BMC Med Genomics. 2026 Jul 22; 19(Suppl 1).Ko S, Li H, … Choi YBM
  • CONCLUSIONS: This study highlights the complementary strengths of AlphaFold-based and sequence-based methods for predicting pMHC-II binding core regions. AlphaFold-based methods excel in predicting positive binders, while NetMHCIIpan is highly effective at identifying non-binders. Future research should focus on improving the prediction of unbound peptides for AlphaFold-based models. Since NetMHCIIpan's binding core predictive ability is already high, future efforts should concentrate on enhancing its binding prediction to further improve overall accuracy.
  • Breakpoint-level characterization of a novel CEP290 tandem duplication in trans with a pathogenic splice-site variant in a patient with Leber congenital amaurosis. [Journal Article]
    BMC Med Genomics. 2026 Jul 21. [Online ahead of print]Xu S, Geng J, … Lu YBM
  • CONCLUSIONS: To our knowledge, this study represents the first breakpoint-resolved characterization of a pathogenic CEP290 tandem duplication encompassing exons 31-53 identified in compound heterozygosity with a pathogenic splice-site variant in a patient with early-onset retinal degeneration. The duplication is predicted to disrupt the CEP290 coding sequence, resulting in a frameshift, premature termination codon, and loss of the C-terminal functional domain. These findings expand the spectrum of pathogenic structural variants in CEP290 and underscore the value of whole-genome sequencing and breakpoint-level analysis for resolving genetically unexplained inherited retinal disorders.
  • Clinical and molecular characterization of TCF12 variants in an Asian pediatric cohort with craniosynostosis. [Journal Article]
    BMC Med Genomics. 2026 Jul 13; 19(1).Zhong R, Zheng L, … Wang GBM
  • CONCLUSIONS: This study provides additional clinical and molecular data on TCF12-related craniosynostosis in a pediatric cohort from an Asian population. Our findings support haploinsufficiency as the central pathogenic mechanism, primarily driven by truncating variants affecting the C-terminal bHLH domain. The marked clinical heterogeneity, the presence of mild or evolving phenotypes, and incomplete penetrance observed in our cohort underscore the importance of early diagnosis and longitudinal clinical surveillance in affected families.